Page last updated: 2024-10-17

3,4-dihydroxyphenylacetic acid and Congenital Zika Syndrome

3,4-dihydroxyphenylacetic acid has been researched along with Congenital Zika Syndrome in 1 studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W1
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1

Other Studies

1 other study available for 3,4-dihydroxyphenylacetic acid and Congenital Zika Syndrome

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020